SHAREHOLDERS AGREEMENTShareholder Agreement • March 17th, 2022 • Chinook Therapeutics, Inc. • Pharmaceutical preparations • New York
A The Group (as defined below) intends to engage in the businesses of the research, development, manufacturing, sales and commercialization of products targeting kidney diseases (the “Business”).
January 28, 2022Separation Agreement • March 17th, 2022 • Chinook Therapeutics, Inc. • Pharmaceutical preparations • California
This letter confirms the agreement (“Agreement”) between you and Chinook Therapeutics, Inc. (the “Company”) concerning the terms of your resignation and offers you the separation compensation we discussed in exchange for a general release of claims and covenant not to sue.
LICENSE AGREEMENTLicense Agreement • March 17th, 2022 • Chinook Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”) is entered into on November 24, 2021 (the “Execution Date”), by and between Chinook Therapeutics, Inc., a Delaware corporation with a place of business at 400 Fairview Ave North, 9th Floor, Seattle, WA 98109 (“Chinook” or “Licensor”), and SanReno Therapeutics (Hong Kong) Limited, a limited company organized under the laws of Hong Kong (“Licensee”) and wholly owned subsidiary of SanReno Therapeutics Holdings Limited. Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
